Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

BACKGROUND: In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving previously untreated patients with advanced renal-cell carcinoma compared avelumab plus axitinib with the standard-of-car...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Motzer, Robert J., Penkov, Konstantin, Haanen, John, Rini, Brian, Albiges, Laurence, Campbell, Matthew T., Venugopal, Balaji, Kollmannsberger, Christian, Negrier, Sylvie, Uemura, Motohide, Lee, Jae L., Vasiliev, Aleksandr, Miller, Wilson H., Gurney, Howard, Schmidinger, Manuela, Larkin, James, Atkins, Michael B., Bedke, Jens, Alekseev, Boris, Wang, Jing, Mariani, Mariangela, Robbins, Paul B., Chudnovsky, Aleksander, Fowst, Camilla, Hariharan, Subramanian, Huang, Bo, di Pietro, Alessandra, Choueiri, Toni K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6716603/
https://ncbi.nlm.nih.gov/pubmed/30779531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1816047
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados